Search Within

Elisa De Stanchina

  1. "Marc Ladanyi"
Formats
  1. Journal Article (27)
  2. Meeting Abstract (15)
  3. Research Letter (1)
Groups
  1. Department of Pathology and Laboratory Medicine (43)
  2. GSK Faculty (43)
  3. Human Oncology and Pathogenesis Program (43)
  4. Tow Center for Developmental Oncology (TCDO) (43)
  5. Sloan Kettering Institute Postdocs (37)
  6. Department of Medicine (27)

More Groups

People
  1. Marc Ladanyi (43)
  2. Romel Somwar (33)
  3. Marissa Mattar (27)
  4. Inna Khodos (26)
  5. Igor Odintsov (15)
  6. Alexander Drilon (13)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (3)
  4. 2022 (11)
  5. 2021 (5)
  6. 2020 (3)

More Years

Publications
  1. Cancer Research (7)
  2. Journal of Thoracic Oncology (6)
  3. Clinical Cancer Research (5)
  4. Cancer Discovery (3)
  5. Journal of Clinical Oncology (3)
  6. Disease Models & Mechanisms (2)

More Publications

Publishers
  1. American Association for Cancer Research (17)
  2. Elsevier Inc. (8)
  3. American Society of Clinical Oncology (5)
  4. American Association for the Advancement of Science (2)
  5. Company of Biologists (2)
  6. Nature Publishing Group (2)

More Publishers

Results (43)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RRAS and RRAS2 hotspot mutations as novel actionable oncogenic drivers in lung adenocarcinoma
    Meeting Abstract

    Ladanyi, M.; Yang, S. R.; Zhang, T.; de Stanchina, E.; Somwar, R.
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor
    Journal Article

    Zhang, T.; Febres-Aldana, C. A.; Liu, Z.; Dix, J. M.; Cheng, R.; Dematteo, R. G.; Lui, A. J. W.; Khodos, I.; Gili, L.; Mattar, M. S.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Combination of MDM2 and targeted kinase inhibitors results in prolonged tumor control in lung adenocarcinomas with oncogenic tyrosine kinase drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Smith, R. S.; Vojnic, M.; Hayashi, T.; Khodos, I.; Markov, V.; Liu, Z.; Lui, A. J. W.; Bloom, J. L.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy
    Journal Article

    Kazansky, Y.; Cameron, D.; Mueller, H. S.; Demarest, P.; Zaffaroni, N.; Arrighetti, N.; Zuco, V.; Kuwahara, Y.; Somwar, R.; Ladanyi, M.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
    Journal Article

    Miyazaki, I.; Odintsov, I.; Ishida, K.; Lui, A. J. W.; Kato, M.; Suzuki, T.; Zhang, T.; Wakayama, K.; Kurth, R. I.; Cheng, R.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Journal Article

    Paik, P. K.; Fan, P. D.; Qeriqi, B.; Namakydoust, A.; Daly, B.; Ahn, L.; Kim, R.; Plodkowski, A.; Ni, A.; Chang, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Prospective clinical genomic profiling of Ewing sarcoma: ERF and FGFR1 mutations as recurrent secondary alterations of potential biologic and therapeutic relevance
    Journal Article

    Ogura, K.; Elkrief, A.; Bowman, A. S.; Koche, R. P.; de Stanchina, E.; Benayed, R.; Mauguen, A.; Mattar, M. S.; Khodos, I.; Meyers, P. A.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Tractable patient-derived models for preclinical therapeutic studies of CNS metastases
    Meeting Abstract

    Vojnic, M.; Odintsov, I.; Offin, M. D.; Lui, A. J. W.; Khodos, I.; Chang, Q.; Mattar, M. S.; De Stanchina, E.; Ladanyi, M.; Somwar, R.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases
    Meeting Abstract

    Odintsov, I.; Lui, A. J. W.; Ishizawa, K.; Miyazaki, I.; Khodos, I.; Wakayama, K.; Vojnic, M.; Hagen, C. J.; Chang, Q.; Bonifacio, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save